SEC Tracker
Get the app

Annovis Bio ANVS

Annovis Bio approves share increase and equity plan amendment

Item 5.03 Amends charter or bylaws, Item 5.07 Shareholder vote results

Form
8-K
Filed
Importance
Notable
  1. 28,301,063 shares represented, 66.31% of outstanding
  2. Proposal 1: 85.61% voted for increasing common stock shares to 140M
  3. Proposal 2: 83.76% voted for amending equity incentive plan

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Annovis Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  2. Karyopharm Therapeutics KPTI public float $37M, Jun 30, 2025
  3. Grace Therapeutics GRCE public float $35M, Sep 30, 2025
  4. BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
  5. Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025